Germline Testing for Prostate Cancer Prognosis: Implications for Active Surveillance

Urol Clin North Am. 2021 Aug;48(3):401-409. doi: 10.1016/j.ucl.2021.04.003. Epub 2021 Jun 10.ABSTRACTAvailable evidence supports routine implementation of germline genetic testing for many aspects of prostate cancer (PCa) decision making. The purpose of obtaining genetic testing for newly diagnosed men would be focused on identifying mutations that predispose to aggressive PCa. Based on an evidence-based review, the authors review germline rare pathogenic mutations in several genes that are significantly associated with aggressiveness, metastases, and mortality. Then recent studies of these germline mutations in predicting tumor grade reclassification among patients undergoing active surveillance are discussed. Single nucleotide polymorphisms-based polygenic risk scores in differentiating PCa aggressiveness and prognosis are reviewed.PMID:34210494 | DOI:10.1016/j.ucl.2021.04.003

Source: The Urologic Clinics of North America - July 2, 2021 Category: Urology & Nephrology Authors: Brian T Helfand Jianfeng Xu Source Type: research